Table 1.
Characteristics of 188 Patients who Received Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
| Group | COXi | No-COXi | p Value |
|---|---|---|---|
| No. patients | 120 | 68 | |
| Sex, no. (%) | 0.99 | ||
| Male | 95 (79) | 53 (78) | |
| Female | 25 (21) | 15 (22) | |
| Age at diagnosis, median (IQR), years | 61 (55–67) | 57 (48-68) | 0.135 |
| Age at treatment, median (IQR), years | 66 (59–71) | 60 (51–71) | 0.011 |
| Race, no. (%) | 0.56 | ||
| White | 111 (94) | 60 (90) | |
| Black | 2 (2) | 2 (3) | |
| Hispanic | 4 (3) | 3 (4) | |
| Asian | 1 (1) | 2 (3) | |
| Type of ICI, no. (%) | 0.81 | ||
| PD-1 inhibitors | 70 (58) | 35 (52) | |
| PD-1 inhibitors/CTLA4 inhibitors | 24 (20) | 16 (24) | |
| PD-1 inhibitors + TKI | 7 (6) | 4 (6) | |
| PD-1 + interleukins under clinical trials | 19 (16) | 13 (19) | |
| Histology subtype, no. (%) | 1.0 | ||
| Clear cell RCC | 115 (96) * | 65 (96) | |
| Non–clear-cell RCC | 5 (4.1) * | 3 (4.4) | |
| IMDC risk ^, no. (%) | 111 | 60 | 0.112 |
| Favorable | 36 (32) * | 11 (18) * | |
| Intermediate | 59 (53) * | 41 (68) * | |
| Poor risk | 16 (14) * | 8 (13) * | |
| Lines of prior therapy, no. (%) | 0.503 | ||
| 0 | 45 (38) | 31 (46) | |
| 1 | 35 (29) | 17 (25) | |
| 2 | 24 (20) | 9 (13) | |
| 3 or more | 16 (13) | 11 (16) | |
| NLR, no., median (95% CI) # | 103, 3.2 (1.4–8.7) | 57, 3.3 (1.2–11.4) | 0.869 |
Abbreviations: COXi, cyclooxygenase inhibitor; CTLA4, cytotoxic T-lymphocyte-associated protein 4; ICIs, immune checkpoint inhibitors; IMDC, International Metastatic RCC Database Consortium Risk model; IQR, interquartile range; NLR, neutrophil-to-lymphocyte ratio; PD-1, programmed cell death protein 1; RCC, renal cell carcinoma; TKIs, tyrosine kinase inhibitors. * The percentages may not add up to 100 due to rounding. ^ Only 171 patients had available data at the time of metastatic disease to calculate the IMDC risk group. # Only 160 patients had available neutrophils and lymphocytes numbers during metastatic disease.